Kyverna Therapeutics, an Emeryville, CA-based clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases, closed a $60m Series B financing round extension, bringing the total Series B financing round to $145m.
New investors, Bain Capital Life Sciences and GordonMD® Global Investments LP, joined existing investors Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital, and others.
The company intends to use the proceeds for clinical development of novel fully human anti-CD19 CAR T-cell therapies for autoimmune diseases.
Kyverna Therapeutics has developed a therapeutic platform that combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Its pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.
Kyverna’s anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201, specifically target CD19, a protein expressed on the surface of B cells which is involved in various types of autoimmune diseases including lupus nephritis.
KYV-101 is an autologous version of a novel, fully human clinical-stage anti-CD19 chimeric antigen receptor (CAR) T-cell construct with properties well suited for use in B cell-driven autoimmune diseases such as lupus nephritis and other B cell-driven autoimmune diseases.
KYV-201 is an allogeneic version of Kyverna’s novel, fully human clinical-stage anti-CD19 chimeric antigen receptor (CAR) T-cell construct with properties suited for use in B cell-driven autoimmune diseases such as lupus nephritis and other B cell-driven autoimmune diseases. KYV-201 leverages the power of genome editing through a proprietary ex vivo CRISPR/Cas9-based allogeneic platform for use in B cell-mediated autoimmune diseases.
FinSMEs
03/08/2023